4D Molecular Therapeutics Missed Consensus Estimates
Thursday, May 8, 2025 at 4:05 PM ET
4D Molecular Therapeutics (FDMT) reported a loss of $0.86 per share on revenue of $0.01 million for the first quarter ended March 2025. The consensus estimate was a loss of $0.84 per share on revenue of $1.08 million. The company missed consensus estimates by 2.38% while revenue fell 50.00% compared to the same quarter a year ago.
4DMT is a clinical-stage company harnessing the power of directed evolution for targeted gene therapies.
Earnings Whisper Grade
Power Rating
-
-
Reported Earnings
$-0.86
Earnings Whisper®
-
Consensus Estimate
$-0.84
Earnings Surprise
Earnings Growth
Reported Revenue
$14.00 Thou
Revenue Estimate
$1.08 Mil
Revenue Surprise
Revenue Growth